Company DescriptionPredictive Biosciences is a molecular diagnostics company headquartered in Lexington, MA. Launched in 2006 with a $10 million Series A financing, the company was jointly founded by leading healthcare investors, experienced entrepreneurs, and internationally-renowned scientists in the areas of tumor growth, tumor angiogenesis, and cancer markers. Predictive Biosciences possesses an extensive IP portfolio – including 18 issued US patents – and deep in-house expertise in proteomics, diagnostics, oncology, and tumor biomarkers.

Proceeds PurposesProceeds from the Series C financing will be used to complete multi-center clinical trials for Predictive’s CertNDx bladder cancer assay and support its commercial launch through the company’s CLIA certified laboratories.